The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER
Abstract
PURPOSE: We present the long-term outcome and tolerance of 3-dimensional (D) conformal and intensity modulated radiation therapy for localized prostate cancer. MATERIALS AND METHODS: Between October 1988 and December 1998, 1,100 patients with clinical stages T1c-T3 prostate cancer were treated with 3-D conformal or intensity modulated radiation therapy. Patients were categorized into prognostic risk groups based on pretreatment prostate specific antigen (PSA), Gleason score and clinical stage. Sextant biopsies were performed 2.5 years or greater after treatment to assess local control. PSA relapse was defined according to the consensus guidelines of the American Society for Therapeutic Radiation Oncology. Late toxicity was classified according to the Radiation Therapy Oncology Group morbidity grading scale. Median followup was 60 months. RESULTS: At 5 years the PSA relapse-free survival rate in patients at favorable, intermediate and unfavorable risk was 85% (95% confidence interval [CI] +/- 4), 58% (95% CI +/- 6) and 38% (95% CI +/- 6), respectively (p <0.001). Radiation dose was the most powerful variable impacting PSA relapse-free survival in each prognostic risk group. The 5-year actuarial PSA relapse-free survival rate for patients at favorable risk who received 64.8 to 70.2 Gy. was 77% (95% CI +/- 8) compared to 90% (95% CI +/- 8) for those treated with 75.6 to 86.4 Gy. (p = 0.04) [corrected]. The corresponding rates were 50% (95% CI +/- 8) versus 70% (95% CI +/- 6) in intermediate risk cases (p = 0.001), and 21% (95% CI +/- 8) versus 47% (95% CI +/- 6) in unfavorable risk cases (p = 0.008) [corrected]. Only 4 of 41 patients (10%) who received 81 Gy. had a positive biopsy 2.5 years or greater after treatment compared with 27 of 119 (23%) after 75.6, 23 of 68 (34%) after 70.2 and 13 of 24 (54%) after 64.8 Gy. The incidence of toxicity after 3-D conformal radiation therapy was dose dependent. The 5-year actuarial rate of grade 2 rectal toxicity in patients who received 75.6 Gy. or greater was 14% (95% CI +/- 2) compared with 5% (95% CI +/- 2) in those treated at lower dose levels (p <0.001). Treatment with intensity modulated radiation therapy significantly decreased the incidence of late grade 2 rectal toxicity since the 3-year actuarial incidence in 189 cases managed by 81 Gy. was 2% (95% CI +/- 2) compared with 14% (95% CI +/- 2) in 61 managed by the same dose of 3-D conformal radiation therapy (p = 0.005). The 5-year actuarial rate of grade 2 urinary toxicity in patients who received 75.6 Gy. or greater 3-D conformal radiation therapy was 13% compared with 4% in those treated up to lower doses (p <0.001). Intensity modulated radiation therapy did not affect the incidence of urinary toxicity. CONCLUSIONS: Sophisticated conformal radiotherapy techniques with high dose 3-D conformal and intensity modulated radiation therapy improve the biochemical outcome in patients with favorable, intermediate and unfavorable risk prostate cancer. Intensity modulated radiation therapy is associated with minimal rectal and bladder toxicity, and, hence, represents the treatment delivery approach with the most favorable risk-to-benefit ratio.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer
Kattan, M. W., Eastham, J. A., Stapleton, A. M. F., Wheeler, T. M., & Scardino, P. T. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.10.766 · Cited by 1,242
Consensus statement: Guidelines for PSA following radiation therapy1
AMERICANSOCIETYFORTHERAPEUTICR (1997) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00002-3 · Cited by 1,151
Zelefsky, M., Leibel, S., Gaudin, P., Kutcher, G., Fleshner, N., Venkatramen, E. S., Reuter, V., Fair, W., Ling, C. C., & Fuks, Z. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00091-1 · Cited by 924
Self-citationPilepich, M. V., Caplan, R., Byhardt, R. W., Lawton, C. A., Gallagher, M. J., Mesic, J. B., Hanks, G. E., Coughlin, C. T., Porter, A., Shipley, W. U., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1013 · Cited by 607
Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer
Zelefsky, M. J., Fuks, Z., Happersett, L., Lee, H. J., Ling, C. C., Burman, C. M., Hunt, M., Wolfe, T., Venkatraman, E. S., Jackson, A., et al. (2000) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(99)00100-0 · Cited by 543
Self-citationPollack, A., Zagars, G. K., Smith, L. G., Lee, J. J., von Eschenbach, A. C., Antolak, J. A., Starkschall, G., & Rosen, I. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3904 · Cited by 521
Radiation Therapy for Clinically Localized Prostate Cancer: A Multi-institutional Pooled Analysis
Shipley, W. U., Thames, H. D., Sandler, H. M., Hanks, G. E., Zietman, A. L., Perez, C. A., Kuban, D. A., Hancock, S. L., & Smith, C. D. (1999) · JAMA · doi:10.1001/jama.281.17.1598 · Cited by 440
Lawton, C. A., Won, M., Pilepich, M. V., Asbell, S. O., Shipley, W. U., Hanks, G. E., Cox, J. D., Perez, C. A., Sause, W. T., Doggett, S. R. L., et al. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90732-j · Cited by 424
Storey, M. R., Pollack, A., Zagars, G., Smith, L., Antolak, J., & Rosen, I. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00700-8 · Cited by 413
AMLING, C. L., BLUTE, M. L., BERGSTRALH, E. J., SEAY, T. M., SLEZAK, J., & ZINCKE, H. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67457-5 · Cited by 368
Zelefsky, M. J., Cowen, D., Fuks, Z., Shike, M., Burman, C., Jackson, A., Venkatramen, E. S., & Leibel, S. A. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990601)85:11<2460::aid-cncr23>3.0.co;2-n · Cited by 336
Self-citationLaverdière, J., Gomez, J., Cusan, L., Raul Suburu, E., Diamond, P., Lemay, M., Candas, B., Fortin, A., & Labrie, F. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00513-5 · Cited by 309
The effect of dose on local control of prostate cancer
Hanks, G. E., Martz, K. L., & Diamond, J. J. (1988) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(88)90224-6 · Cited by 273
Zelefsky, M. J., Leibel, S. A., Burman, C. M., Kutcher, G. J., Harrison, A., Happersett, L., & Fuks, Z. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90563-0 · Cited by 169
Self-citationDose selection for prostate cancer patients based on dose comparison and dose response studies
Hanks, G. E., Hanlon, A. L., Pinover, W. H., Horwitz, E. M., Price, R., & Schultheiss, T. E. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00498-8 · Cited by 156
RADICAL PERINEAL PROSTATECTOMY: ONCOLOGICAL OUTCOME DURING A 20-YEAR PERIOD
Iselin, C. E., Robertson, J. E., & Paulson, D. F. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(01)62088-3 · Cited by 130
Vicini, F. A., Kestin, L. L., & Martinez, A. A. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00235-7 · Cited by 124
Crook, J. M., Bahadur, Y. A., Robertson, S. J., Perry, G. A., & Esche, B. A. (1997) · Cancer · Cited by 123
Polascik, T. J., Pound, C. R., DeWeese, T. L., & Walsh, P. C. (1998) · Urology · doi:10.1016/s0090-4295(98)00153-8 · Cited by 90
The definition of biochemical failure in patients treated with definitive radiotherapy
Kattan, M. W., Fearn, P., Leibel, S. A., & Potters, L. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01359-6 · Cited by 71
Self-citationConnell, P. P., Ignacio, L., McBride, R. B., Weichselbaum, R. R., & Vijayakumar, S. (1999) · Urology · doi:10.1016/s0090-4295(99)00253-8 · Cited by 36
Pollack, A., Zagars, G. K., Smith, L., Antolak, J. A., & Rosen, I. I. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)90022-6 · Cited by 35
Cited by
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial
Pollack, A., Zagars, G. K., Starkschall, G., Antolak, J. A., Lee, J. J., Huang, E., von Eschenbach, A. C., Kuban, D. A., & Rosen, I. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02829-8 · Cited by 1,333
Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer
Kuban, D. A., Tucker, S. L., Dong, L., Starkschall, G., Huang, E. H., Cheung, M. R., Lee, A. K., & Pollack, A. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.06.054 · Cited by 1,232
Zietman, A. L., DeSilvio, M. L., Slater, J. D., Rossi, C. J., Miller, D. W., Adams, J. A., & Shipley, W. U. (2005) · JAMA · doi:10.1001/jama.294.10.1233 · Cited by 1,224
Effects of radiation on normal tissue: consequences and mechanisms
Stone, H. B., Coleman, C. N., Anscher, M. S., & McBride, W. H. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01191-4 · Cited by 931
Zelefsky, M. J., Fuks, Z., Hunt, M., Yamada, Y., Marion, C., Ling, C. C., Amols, H., Venkatraman, E. S., & Leibel, S. A. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02857-2 · Cited by 775
Self-citation
Metadata
- Authors
- ZELEFSKY, M. J., FUKS, Z., HUNT, M., LEE, H. J., LOMBARDI, D., LING, C. C., REUTER, V. E., VENKATRAMAN, E. S., & LEIBEL, S. A.
- Venue
- Journal of Urology
- Published
- 2001-09
- Volume
- 166
- Issue
- 3
- Pages
- 876-881
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2103429819
- Cited by
- 697
- References
- 28
- FWCI
- 39.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.